12:00 AM
Nov 09, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Laninamivir: Phase III started

The partners began the double-blind, placebo-controlled, Japanese Phase III SHIELD trial to evaluate inhaled CS-8958 in subjects from households with influenza-infected...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >